Glucagon Receptor
GCGR is the receptor for glucagon. Retatrutide is the first incretin agonist to add glucagon-receptor activity to GLP-1 and GIP — that combination is part of why phase 2 trials saw weight loss exceed any prior incretin agonist. So far no common GCGR variant has been shown to substantially change retatrutide response, but we surface the gene because the field is moving quickly.
Gene2Rx covers 0 medications with published pharmacogenetic guidance for GCGR, drawn from CPIC and FDA sources. Each drug links to its full pharmacogenetics page.
This page lists drugs affected by GCGR. A Gene2Rx report tells you which metabolizer group you fall into, and what that means for every medication on this list.
Get your report Look up a medicationInformational only, not medical advice. The presence of a GCGR pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.